PMID- 31856933
OWN - NLM
STAT- MEDLINE
DCOM- 20201119
LR  - 20210217
IS  - 1555-3906 (Electronic)
IS  - 0965-0407 (Print)
IS  - 0965-0407 (Linking)
VI  - 28
IP  - 3
DP  - 2020 May 29
TI  - The Comprehensive Analysis of Efficacy and Safety of CalliSpheres((R)) Drug-Eluting 
      Beads Transarterial Chemoembolization in 367 Liver Cancer Patients: A 
      Multiple-Center, Cohort Study.
PG  - 249-271
LID - 10.3727/096504019X15766663541105 [doi]
AB  - This study aimed to investigate the efficacy, safety, and prognostic factors of 
      drug-eluting beads transarterial chemoembolization (DEB-TACE) in treating Chinese 
      patients with liver cancer. A total of 367 liver cancer patients from 24 medical 
      centers were consecutively enrolled in this multiple-center, prospective cohort 
      study, including 275 hepatocellular carcinoma (HCC) cases, 37 intrahepatic 
      cholangiocarcinoma (ICC) cases, and 55 secondary liver cancer cases. All the 
      patients received CalliSpheres((R)) DEB-TACE treatment. Treatment response, overall 
      survival (OS), change of liver function, and adverse events (AEs) were assessed. 
      DEB-TACE treatment achieved 19.9% complete response (CR) and 79.6% objective 
      response rate (ORR), with mean OS of 384 days [95% confidence interval (CI): 
      375-393 days]. CR and ORR were both higher in HCC patients compared with primary 
      ICC patients and secondary liver cancer patients, while no difference was 
      discovered in OS. Portal vein invasion was an independent risk factor for CR, 
      while portal vein invasion, previous conventional TACE (cTACE) treatment, and 
      abnormal blood creatinine (BCr) were independent risk factors for ORR. In 
      addition, largest nodule size >/=5.0 cm, abnormal albumin (ALB), and abnormal total 
      bilirubin (TBIL) independently correlated with unfavorable OS. Most liver 
      function indexes were recovered to baseline levels at 1-3 months after DEB-TACE. 
      Common AEs were pain, fever, vomiting, and nausea; most of them were at mild 
      grade. CalliSpheres((R)) DEB-TACE is efficient and well tolerated in Chinese liver 
      cancer patients. Portal vein invasion, previous cTACE treatment, largest nodule 
      size, abnormal BCr, ALB, and TBIL correlate with worse prognosis independently.
FAU - Peng, Zhiyi
AU  - Peng Z
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine, 
      Zhejiang UniversityHangzhouChina.
FAU - Cao, Guohong
AU  - Cao G
AD  - Department of Radiology, Shulan (Hangzhou) Hospital, Zhejiang University 
      International HospitalHangzhouChina.
FAU - Hou, Qinming
AU  - Hou Q
AD  - Department of Radiology, Xixi Hospital of Hangzhou, Hangzhou 6th People's 
      HospitalHangzhouChina.
FAU - Li, Ling
AU  - Li L
AD  - Department of Liver Oncology, Ningbo No. 2 HospitalNingboChina.
FAU - Ying, Shihong
AU  - Ying S
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine, 
      Zhejiang UniversityHangzhouChina.
FAU - Sun, Junhui
AU  - Sun J
AD  - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of 
      Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of 
      Medicine, Zhejiang UniversityHangzhouChina.
FAU - Zhou, Guanhui
AU  - Zhou G
AD  - Hepatobiliary and Pancreatic Interventional Treatment Center, Division of 
      Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of 
      Medicine, Zhejiang UniversityHangzhouChina.
FAU - Zhou, Jian
AU  - Zhou J
AD  - Department of Radiology, Hangzhou Cancer HospitalHangzhouChina.
FAU - Zhang, Xin
AU  - Zhang X
AD  - Department of Radiology, The First Affiliated Hospital, College of Medicine, 
      Zhejiang UniversityHangzhouChina.
FAU - Ji, Wenbin
AU  - Ji W
AD  - Department of Radiology, Taizhou Hospital of Zhejiang ProvinceLinhaiChina.
FAU - Yu, Zhihai
AU  - Yu Z
AD  - Department of Vascular and Interventional Radiology, The Affiliated Hospital of 
      Medical College of Ningbo UniversityNingboChina.
FAU - Li, Tiefeng
AU  - Li T
AD  - Department of Radiology, Beilun District People's Hospital of NingboNingboChina.
FAU - Zhu, Dedong
AU  - Zhu D
AD  - Department of Liver Oncology, Ningbo No. 2 HospitalNingboChina.
FAU - Hu, Wenhao
AU  - Hu W
AD  - Department of Intervention, The First Affiliated Hospital of Wenzhou Medical 
      UniversityWenzhouChina.
FAU - Ji, Jiansong
AU  - Ji J
AD  - Department of Radiology, Lishui Central Hospital, Lishui Hospital of Zhejiang 
      University, The Fifth Affiliated Hospital of Wenzhou Medical 
      UniversityLishuiChina.
FAU - Du, Haijun
AU  - Du H
AD  - Department of Intervention, Dongyang People's HospitalDongyangChina.
FAU - Shi, Changsheng
AU  - Shi C
AD  - Department of Intervention, The Third Affiliated Hospital of Wenzhou Medical 
      UniversityRuianChina.
FAU - Guo, Xiaohua
AU  - Guo X
AD  - Department of Intervention, Jinhua Central HospitalJinhuaChina.
FAU - Fang, Jian
AU  - Fang J
AD  - Department of Hepatobiliary Surgery, Quzhou People's HospitalQuzhouChina.
FAU - Han, Jun
AU  - Han J
AD  - Department of Intervention, Jiaxing First HospitalJiaxingChina.
FAU - Gu, Wenjiang
AU  - Gu W
AD  - Department of Intervention, Jiaxing Second HospitalJiaxingChina.
FAU - Xie, Xiaoxi
AU  - Xie X
AD  - Interventional Center, Xinchang People's HospitalShaoxingChina.
FAU - Sun, Zhichao
AU  - Sun Z
AD  - Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese 
      Medical UniversityHangzhouChina.
FAU - Xu, Huanhai
AU  - Xu H
AD  - Division of Digestive Endoscopy, Yueqing City People's HospitalYueqingChina.
FAU - Wu, Xia
AU  - Wu X
AD  - Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University College 
      of MedicineHangzhouChina.
FAU - Hu, Tingyang
AU  - Hu T
AD  - Department of Intervention, Zhejiang Provincial People's HospitalHangzhouChina.
FAU - Huang, Jing
AU  - Huang J
AD  - Department of Hepatobiliary Surgery, Ningbo Medical Center, Lihuili Eastern 
      HospitalNingboChina.
FAU - Hu, Hongjie
AU  - Hu H
AD  - Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University College 
      of MedicineHangzhouChina.
FAU - Zheng, Jiaping
AU  - Zheng J
AD  - Department of Intervention, Zhejiang Cancer HospitalHangzhouChina.
FAU - Luo, Jun
AU  - Luo J
AD  - Department of Intervention, Zhejiang Cancer HospitalHangzhouChina.
FAU - Chen, Yutang
AU  - Chen Y
AD  - Department of Intervention, Zhejiang Cancer HospitalHangzhouChina.
FAU - Yu, Wenqiang
AU  - Yu W
AD  - Department of Intervention, Zhejiang Provincial People's HospitalHangzhouChina.
FAU - Shao, Guoliang
AU  - Shao G
AD  - Department of Intervention, Zhejiang Cancer HospitalHangzhouChina.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20191219
PL  - United States
TA  - Oncol Res
JT  - Oncology research
JID - 9208097
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Carcinoma, Hepatocellular/diagnosis/mortality/*therapy
MH  - Chemoembolization, Therapeutic/adverse effects/*methods
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/diagnosis/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Treatment Outcome
PMC - PMC7851534
COIS- The authors declare no conflicts of interest.
EDAT- 2019/12/21 06:00
MHDA- 2020/11/20 06:00
PMCR- 2020/05/29
CRDT- 2019/12/21 06:00
PHST- 2019/12/21 06:00 [pubmed]
PHST- 2020/11/20 06:00 [medline]
PHST- 2019/12/21 06:00 [entrez]
PHST- 2020/05/29 00:00 [pmc-release]
AID - OR1410 [pii]
AID - 10.3727/096504019X15766663541105 [doi]
PST - ppublish
SO  - Oncol Res. 2020 May 29;28(3):249-271. doi: 10.3727/096504019X15766663541105. Epub 
      2019 Dec 19.